Compound News and Research

RSS

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.

17 Oct 2012

Brain’s biological mechanisms may contribute to diet-related disorders

Studies released today explore the neurological component of dietary disorders, uncovering evidence that the brain's biological mechanisms may contribute to significant public health challenges - obesity, diabetes, binge eating, and the allure of the high-calorie meal. The findings were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

17 Oct 2012

Positive results from PROLOR's Rpeg preclinical toxicology study

PROLOR Biotech, Inc. today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology.

17 Oct 2012

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Resverlogix Corp. today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

17 Oct 2012

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

For decades, patients with Parkinson's disease (PD) have had the same experience. Their hands start to shake uncontrollably, their limbs become rigid and they lose their balance. Years before those movement problems set in, many begin struggling with fainting, incontinence, sexual dysfunction, anxiety and depression. Many patients are still treated with a 42-year-old drug called L-DOPA, which temporarily staves off symptoms but can itself cause heart arrhythmias, stomach bleeding and hallucinations.

16 Oct 2012

Curcumin can inhibit formation of prostate cancer metastases

Powdered turmeric has been used for centuries to treat osteoarthritis and other illnesses. Its active ingredient, curcumin, inhibits inflammatory reactions. A new study led by a research team at Ludwig-Maximilians-Universit-t (LMU) in Munich now shows that it can also inhibit formation of metastases.

13 Oct 2012

State roundup: Minn. says health exchange will cost $40 million

Minnesota budget officials estimate it could cost the state as much as $40 million to run its health insurance exchange in 2015. The state-based online insurance marketplaces are a cornerstone of the federal health care overhaul.

12 Oct 2012

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.

12 Oct 2012

Nelfinavir slows progress of HER2-positive tumor cells

After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.

12 Oct 2012

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

The American Association for Cancer Research will host the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research at the Hilton Anaheim from Oct. 16-19, 2012.

12 Oct 2012

Investigators provide overview of role of dopamine in modulating the immune system

Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.

11 Oct 2012

New drug candidate improves cognitive function of rats with Alzheimer's-like mental impairment

Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.

11 Oct 2012

Kynurenic acid levels increased in bipolar patients with psychotic features

Bipolar disorder patients with a history of psychotic features have higher cerebrospinal fluid concentrations of kynurenic acid (KYNA) than those without such features, research shows.

9 Oct 2012

Liquorice-based nanotech material for sterilizing medical devices

A nanotech material containing an extract from liquorice can be used to sterilize and protect medical devices and implants which include biological components, and protects these functional bio-components during the sterilization process.

8 Oct 2012

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.

8 Oct 2012

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

6 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting. The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way.

5 Oct 2012

BPA exposure can impact thyroid hormones in pregnant women and newborns

Bisphenol A (BPA), an estrogen-like compound that has drawn increased scrutiny in recent years, has been linked to changes in thyroid hormone levels in pregnant women and newborn boys, according to a new study by researchers at the University of California, Berkeley.

4 Oct 2012

Compound News and Research

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Brain’s biological mechanisms may contribute to diet-related disorders

Positive results from PROLOR's Rpeg preclinical toxicology study

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

Curcumin can inhibit formation of prostate cancer metastases

State roundup: Minn. says health exchange will cost $40 million

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Nelfinavir slows progress of HER2-positive tumor cells

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

Investigators provide overview of role of dopamine in modulating the immune system

New drug candidate improves cognitive function of rats with Alzheimer's-like mental impairment

Kynurenic acid levels increased in bipolar patients with psychotic features

Liquorice-based nanotech material for sterilizing medical devices

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

BPA exposure can impact thyroid hormones in pregnant women and newborns

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News